HESHAM MOHAMED to Drug Resistance, Neoplasm
This is a "connection" page, showing publications HESHAM MOHAMED has written about Drug Resistance, Neoplasm.
Connection Strength
0.023
-
Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol. 2016 09; 91(9):869-74.
Score: 0.012
-
Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood. 2014 Apr 10; 123(15):2317-24.
Score: 0.011